Zura Bio Ltd (ZURA)

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab ProgramJune 29, 2026 7:30 AM
Business Wire Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027 Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026 Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced several tibulizumab program updates. Zura has completed enrollment of the Phase 2 TibuSHIELD trial of tibulizumab in adults with HS. The TibuSHIELD trial exceeded the target enrollment, with 247 participants enrolled. Zura remains on track to complete enrollment of the Phase 2 TibuSURE trial of tibulizumab in adults with early diffuse cutaneous SSc in early July. The TibuSURE trial has already exceeded the target enrollment of 80 participants. Exceeding enrollment targets in both TibuSHIELD and TibuSURE reflects the significant unmet need facing patients with HS and SSc. Topline data from TibuSHIELD are expected in the fourth quarter of 2026. Topline data from TibuSURE are expected in H1 2027. Building on tibulizumab's bispecific mechanism targeting both interleukin-17 (“IL-17”) and B cell activating factor (“BAFF”), Zura plans to initiate a Phase 2 study in a third immune-mediated indication by year end 2026. Indication expansion of tibulizumab reflects Zura’s belief in the broad potential of IL-17 and BAFF dual pathway inhibition across immune-mediated diseases. Zura plans to announce the new indication prior to study initiation. "Meeting these enrollment milestones reflects the hard work of our team and the commitment of the investigators and patients. Tibulizumab targets both IL-17 and BAFF — pathways that together form a compelling rationale across a range of immune-mediated conditions and that we believe can break through efficacy ceilings in complex immune disorders," said Kiran Nistala, MBBS, PhD, Chief Medical Officer of Zura. "With two readouts ahead and a third indication entering the clinic later this year, the Zura team is executing against the potential for tibulizumab to address the needs of patients across a range of immune-mediated diseases.” Cash and cash equivalents were $225.6 million as of March 31, 2026. Consistent with prior guidance and inclusive of the planned third-indication study, Zura continues to expect its existing cash to fund planned operations through at least the end of 2028. TibuSHIELD TibuSHIELD is a global, Phase 2, randomized, double-blind, placebo-controlled clinical study evaluating the safety, tolerability, and efficacy of tibulizumab in adults with moderate to severe HS. Participants were randomized 1:1:1 to receive two different doses of tibulizumab or placebo. The study includes a 16-week efficacy assessment period followed by a 12-week safety follow-up and an optional open-label extension. The primary endpoint of the study is the percent change from baseline in total abscess and nodule (AN) count at Week 16. Secondary endpoints include the proportion of participants achieving HiSCR50 or HiSCR75, defined as at least a 50% or 75% reduction in AN count without an increase in abscesses or draining fistulas at Week 16. TibuSURE TibuSURE is a global, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating tibulizumab in adults with early diffuse cutaneous systemic sclerosis. The study includes a 24-week double blind efficacy assessment period followed by an optional open-label period following completion. The primary endpoint is change from baseline in modified Rodnan Skin Score (mRSS) at Week 24. Secondary endpoints assessing interstitial lung disease include forced vital capacity and quantitative high-resolution computed tomography. TibuSURE is the first clinical trial designed to evaluate the dual inhibition of IL-17 and BAFF in diffuse cutaneous systemic sclerosis. For additional information, please visit www.clinicaltrials.gov. ABOUT ZURA Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura’s lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa, and TibuSURE, a study in systemic sclerosis. Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026. Additional product candidates, torudokimab (ZB-880) and crebankitug (ZB-168), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. For more information, please visit www.zurabio.com. FORWARD-LOOKING STATEMENTS Any statements contained in this press release that do not describe historical facts may constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “anticipate,” “believe,” “continue,” “could,” “designed to,” “expect,” “goal,” “intend,” “may,” “outlook,” “plan,” “potential,” “should,” “will,” and similar expressions and the negative of such terms, and are based on Zura’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the development and potential therapeutic benefits of tibulizumab; the timing, progress, design and results of Zura’s current and future clinical trials, including the status of enrollment and anticipated reporting of data therefrom; Zura’s plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026; the sufficiency of Zura’s cash resources and projected cash runway, and other statements that are not historical facts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such forward-looking statements. Risks and uncertainties that may cause actual results to differ materially include, but are not limited to: uncertainties inherent in the development of therapeutic product candidates, such as the risk that one or more of Zura’s current or future product candidates may not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Zura’s current or future product candidates; the risk that prior results, including signals of safety, activity or durability of effect observed in preclinical studies or earlier clinical trials, may not be replicated or may not continue in ongoing or future studies or clinical trials; the risk that modeling data indicating therapeutic potential, or clinical evidence from other drug candidates, may not be predictive of results in Zura’s current or future clinical trials; the risk that Zura’s product candidates or procedures in connection with their administration may not have the safety or efficacy profiles anticipated; risks related to the accuracy of Zura’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; uncertainties related to the timing and outcome of the regulatory approval process; unexpected litigation or other disputes; the impact of macroeconomic conditions on Zura’s business, clinical trials and financial position; and other risks and uncertainties to be described in Zura’s Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Zura as of the date hereof. Zura assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260629189605/en/ Investor and media inquiries:
ir@zurabio.com Original: Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 14, 2026 7:30 AM
Business Wire Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on May 13, 2026, the Company granted an inducement award consisting of an option to purchase up to 600,000 Class A Ordinary Shares (the “Option”) to Muzammil Mustufa, the Company’s new Chief Business Officer. The award was approved by the Compensation Committee of the Company’s Board of Directors and granted outside the Company’s 2023 Equity Incentive Plan (the “Plan”), with a grant date of May 13, 2026, as an inducement material to Mr. Mustufa’s employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The award is subject to the terms and conditions and other provisions set forth in the Company’s Plan and the award agreement thereunder. The Option has an exercise price of $4.80 per Class A Ordinary Share, which is equal to the closing price of Zura’s Class A Ordinary Shares on May 13, 2026. The Option will vest over four years, with one fourth (1/4th) of the shares subject to the Option vesting on the one year anniversary of the vesting commencement date, and the remaining shares subject to the Option vesting in equal quarterly installments thereafter, subject to Mr. Mustufa’s continuous service through each such vesting date. ABOUT ZURA Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. For more information, please visit www.zurabio.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260514672655/en/ ir@zurabio.com Original: Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business OfficerMay 13, 2026 7:30 AM
Business Wire Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Muzammil Mustufa as Chief Business Officer (CBO). Mr. Mustufa will oversee corporate strategy, business development, commercial planning, and investor relations efforts. Mr. Mustufa brings 20 years of diversified pharmaceutical and biotechnology experience to Zura, with extensive experience in immunology, rare disease, and other therapeutic areas. Most recently, he served as Vice President of Corporate Strategy at Amicus Therapeutics, where he played an integral part in the global launch and commercialization strategies of two innovative medicines in orphan diseases. He subsequently led integration planning for Amicus in connection with BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of the company. Earlier in his career, Mr. Mustufa held roles at GSK plc, The Frankel Group, and The D.E. Shaw Group. "We are thrilled to welcome Muz to Zura as we approach key clinical and corporate milestones for tibulizumab,” said Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer of Zura Bio. “He brings a rare combination of commercial, strategic, and financial acumen that will elevate and complement our leadership team’s capabilities. Muz is the perfect fit for the company as we continue to explore tibulizumab’s potential to redefine treatment across multiple autoimmune indications as well as pursue opportunities to further advance our mission.” "I am excited to be joining Zura and to contribute during what is clearly a defining period for the company,” said Mr. Mustufa. “The science behind tibulizumab — a first- and only-in-class bispecific simultaneously blocking the IL-17 and BAFF pathways — reflects an approach that has the potential to improve outcomes for patients with serious and complex immune system disorders. I look forward to partnering with Sandeep, our talented team, and the Board of Directors as we prepare for our readouts and the company’s next phase of growth." ABOUT ZURA Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. For more information, please visit www.zurabio.com. FORWARD-LOOKING STATEMENTS Any statements contained in this press release that do not describe historical facts may constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “anticipate,” “believe,” “continue,” “could,” “designed to,” “expect,” “goal,” “intend,” “may,” “outlook,” “plan,” “potential,” “should,” “will,” and similar expressions, and are based on Zura’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the development and potential therapeutic benefits of Zura’s product candidates; the timing, progress, design and results of Zura’s current and future clinical trials, including the anticipated reporting of data therefrom; the potential to expand Zura’s product candidates into additional indications; the sufficiency of Zura’s cash resources and projected cash runway; and other statements that are not historical facts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such forward-looking statements. Risks and uncertainties that may cause actual results to differ materially include, but are not limited to: uncertainties inherent in the development of therapeutic product candidates, such as the risk that one or more of Zura’s current or future product candidates may not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Zura’s current or future product candidates; the risk that prior results, including signals of safety, activity or durability of effect observed in preclinical studies or earlier clinical trials, may not be replicated or may not continue in ongoing or future studies or clinical trials; the risk that modeling data indicating therapeutic potential, or clinical evidence from other drug candidates, may not be predictive of results in Zura’s current or future clinical trials; the risk that Zura’s product candidates or procedures in connection with their administration may not have the safety or efficacy profiles anticipated; risks related to the accuracy of Zura’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; uncertainties related to the timing and outcome of the regulatory approval process; unexpected litigation or other disputes; the impact of macroeconomic conditions on Zura’s business, clinical trials and financial position; and other risks and uncertainties to be described in Zura’s Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Zura as of the date hereof. Zura assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260513568466/en/ Investor and media inquiries:
ir@zurabio.com Original: Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 7:30 AM
Business Wire Continuing advancement of two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with both trials on track to meet anticipated timelines Strengthened leadership team with key executive and Board appointments Completed an underwritten public offering in February 2026, resulting in gross proceeds of approximately $144 million to support advancement of its pipeline Cash and cash equivalents of $225.6 million as of March 31, 2026, which is expected to fund planned operations through at least the end of 2028 Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “We entered the second quarter with a strengthened balance sheet and strengthened team, reflecting growing conviction in bispecific approaches and increased appreciation for IL-17 and BAFF biology” said Sandeep Kulkarni, M.D., Chief Executive Officer of Zura. “We believe we are well positioned—operationally, financially, and scientifically—as we approach anticipated tibulizumab readouts starting later this year.” PROGRAM UPDATES Tibulizumab (ZB-106) During the first quarter of 2026, Zura continued to advance its two ongoing Phase 2 studies of tibulizumab, a bispecific antibody designed to neutralize interleukin-17 (IL-17) and B-cell activating factor (BAFF), key mediators of inflammation and fibrosis. TibuSHIELD (HS): The Phase 2 clinical study evaluating tibulizumab in adult participants with HS is ongoing, with enrollment of approximately 225 patients on track. Topline data are anticipated in the fourth quarter of 2026. TibuSURE (SSc): The Phase 2 clinical study evaluating tibulizumab in adult participants with SSc is ongoing, with enrollment of approximately 80 patients on track. Topline data are anticipated in the first half of 2027. Additionally, Zura is conducting a disciplined evaluation of potential new indications for tibulizumab. Additional Clinical Stage Product Candidates In addition to tibulizumab, Zura is continuing its evaluation of potential development approaches for torudokimab (ZB-880) and crebankitug (ZB-168), informed by current clinical and translational evidence and ongoing assessment of the evolving competitive landscape. CORPORATE HIGHLIGHTS In January 2026, Zura appointed Sandeep Kulkarni, M.D., as Chief Executive Officer. In February 2026, Zura appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors. Dr. Eisner, is a seasoned biotechnology executive with over 25 years of leadership in clinical development and immunology and recently served as Executive Vice President and Chief Medical Officer of Vir Biotechnology. Dr. Nirula, is an accomplished physician-scientist and immunology leader who currently serves as president, and head of research and development at Recludix. He previously served as Senior Vice President and Immunology Therapeutic Area Head at Eli Lilly. In February 2026, Zura closed an underwritten public offering of Class A ordinary shares and pre-funded warrants to purchase Class A ordinary shares, resulting in gross proceeds of approximately $144 million, before deducting underwriting discounts, commissions, and offering expenses. The proceeds are expected to support continued advancement of the Company’s pipeline and broader strategic development initiatives. FIRST QUARTER 2026 FINANCIAL RESULTS Cash Position As of March 31, 2026, Zura had cash and cash equivalents of $225.6 million. Zura expects that its existing cash and cash equivalents are sufficient to support planned operations through at least the end of 2028. Research and Development (R&D) Expenses R&D expenses were $14.7 million for the first quarter of 2026, compared to $10.5 million for the first quarter of 2025. The increase was primarily driven by the continued advancement of Zura’s Phase 2 tibulizumab clinical programs. General and Administrative (G&A) Expenses G&A expenses were $10.8 million for the first quarter of 2026, compared to $8.8 million for the first quarter of 2025. The increase was primarily due to an increase in compensation expense, including share-based compensation and professional fees to support the Company’s growth and advancement of its clinical programs. Net Loss Net loss for the first quarter of 2026 was $24.2 million, or $0.22 per share, compared to $17.4 million, or $0.19 per share, for the same period in 2025. ABOUT ZURA Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. For more information, please visit www.zurabio.com. FORWARD-LOOKING STATEMENTS Any statements contained in this press release that do not describe historical facts may constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “anticipate,” “believe,” “continue,” “could,” “designed to,” “expect,” “goal,” “intend,” “may,” “outlook,” “plan,” “potential,” “should,” “will,” and similar expressions, and are based on Zura’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the development and potential therapeutic benefits of Zura’s product candidates; the timing, progress, design and results of Zura’s current and future clinical trials, including the anticipated reporting of data therefrom; the potential to expand Zura’s product candidates into additional indications; the sufficiency of Zura’s cash resources and projected cash runway; and other statements that are not historical facts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such forward-looking statements. Risks and uncertainties that may cause actual results to differ materially include, but are not limited to: uncertainties inherent in the development of therapeutic product candidates, such as the risk that one or more of Zura’s current or future product candidates may not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Zura’s current or future product candidates; the risk that prior results, including signals of safety, activity or durability of effect observed in preclinical studies or earlier clinical trials, may not be replicated or may not continue in ongoing or future studies or clinical trials; the risk that modeling data indicating therapeutic potential, or clinical evidence from other drug candidates, may not be predictive of results in Zura’s current or future clinical trials; the risk that Zura’s product candidates or procedures in connection with their administration may not have the safety or efficacy profiles anticipated; risks related to the accuracy of Zura’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; uncertainties related to the timing and outcome of the regulatory approval process; unexpected litigation or other disputes; the impact of macroeconomic conditions on Zura’s business, clinical trials and financial position; and other risks and uncertainties to be described in Zura’s Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Zura as of the date hereof. Zura assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. ZURA BIO LIMITED CONSOLIDATED BALANCE SHEETS (In thousands, except share data)       March 31,   December 31,     2026   2025     (unaudited)       Assets             Current assets             Cash and cash equivalents   $ 225,594     $ 109,407   Prepaid expenses and other current assets     1,410       2,903   Total current assets     227,004       112,310   Property and equipment, net     125       126   Other assets     1,512       1,512   Total assets   $ 228,641     $ 113,948                 Liabilities and Shareholders’ Equity             Current liabilities             Accounts payable and accrued expenses   $ 11,745     $ 12,410   Total current liabilities     11,745       12,410   Total liabilities     11,745       12,410                 Commitments and contingencies                           Shareholders’ Equity             Class A Ordinary Shares, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 94,880,710 and 73,680,710 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively     9           7       Additional paid-in capital     465,657       326,078   Accumulated deficit     (248,770 )     (224,547 ) Total shareholders’ equity     216,896       101,538   Total liabilities and shareholders’ equity   $ 228,641     $ 113,948   ZURA BIO LIMITED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except share and per share data)       For the Three Months Ended     March 31,     2026   2025 Operating expenses:             Research and development   $ 14,746     $ 10,474   General and administrative     10,753       8,780   Total operating expenses     25,499       19,254   Loss from operations     (25,499 )     (19,254 ) Other income, net             Interest income     (1,319 )     (1,817 ) Other expense, net     43       5   Total other income, net     (1,276 )     (1,812 ) Loss before income taxes     (24,223 )     (17,442 ) Income tax benefit     —       —   Net loss   $ (24,223 )   $ (17,442 ) Net loss per share, basic and diluted   $ (0.22 )   $ (0.19 ) Weighted-average shares outstanding, basic and diluted     112,222,789       92,964,048     View source version on businesswire.com: https://www.businesswire.com/news/home/20260507541381/en/ Investor and media inquiries:
ir@zurabio.com Original: Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 4:05 PM
Business Wire Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on April 30, 2026, the Company granted inducement awards consisting of options to purchase up to 615,160 Class A Ordinary Shares (the “Options”) to eight newly hired employees. These awards were approved by the Compensation Committee of the Company’s Board of Directors and granted outside the Company’s 2023 Equity Incentive Plan (the “Plan”), with a grant date of April 30, 2026, as inducements material to the new employees’ employments, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and conditions and other provisions set forth in the Company’s Plan and the award agreements thereunder. The Options that were granted have an exercise price of $5.08 per Class A Ordinary Share, which is equal to the closing price of Zura’s Class A Ordinary Shares on April 30, 2026. The Options will each vest over four years, with one fourth (1/4th) of the shares subject to each Option vesting on the one year anniversary of the applicable vesting commencement date, and the remaining shares subject to each Option shall vest in equal quarterly installments thereafter, subject to the employee’s continuous service through such vesting date. ABOUT ZURA Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. For more information, please visit www.zurabio.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260504865719/en/ ir@zurabio.com Original: Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesMarch 19, 2026 4:05 PM
Business Wire

Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc)



Topline data expected from the Phase 2 TibuSHIELD study in HS in the fourth quarter of 2026 and from the Phase 2 TibuSURE study in SSc in the first half of 2027



Cash and cash equivalents of $109.4 million as of December 31, 2025



Completed an underwritten public offering in February 2026 for gross proceeds of approximately $144 million; post-financing cash and cash equivalents expected to support planned operations through at least the end of 2028



Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported financial results for the full year ended December 31, 2025, and provided recent corporate updates.


“2025 was a year of strong execution for Zura, marked by meaningful progress across our Phase 2 programs and a disciplined focus on advancing our clinical strategy,” said Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer of Zura Bio. “We enter 2026 with momentum, supported by a strengthened balance sheet and a focused plan to advance tibulizumab, our lead program and a potential first- and only-in-class bispecific antibody targeting the interleukin-17 and B-cell activating factor pathways. With multiple anticipated Phase 2 data readouts ahead, including topline data from our TibuSHIELD study expected in the fourth quarter of 2026, we believe Zura is well positioned as we move into an important phase of clinical execution and value creation.”


CORPORATE HIGHLIGHTS AND ANTICIPATED MILESTONES


Tibulizumab (ZB-106)


Hidradenitis suppurativa (HS) – Phase 2 TibuSHIELD


The Phase 2 TibuSHIELD clinical study evaluating tibulizumab in adult participants with HS is ongoing. To enhance statistical power, Zura expanded planned enrollment to 225 participants. Topline data are anticipated in the fourth quarter of 2026.


Systemic sclerosis (SSc) – Phase 2 TibuSURE


The Phase 2 TibuSURE clinical study evaluating tibulizumab in adult participants with SSc is ongoing, with topline data anticipated in the first half of 2027.


Additional Clinical Stage Product Candidates


In addition to tibulizumab, Zura is continuing to evaluate potential future development strategies for crebankitug (ZB-168) and torudokimab (ZB-880), informed by available clinical and translational data and by the evolving competitive landscape.


2026 UPDATES SUBSEQUENT TO YEAR END


Leadership Updates


In January 2026, Zura appointed Sandeep Kulkarni, M.D., as Chief Executive Officer. In February 2026, Zura appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors.


Balance Sheet Strengthening


In February 2026, Zura closed an underwritten public offering of Class A ordinary shares and pre-funded warrants to purchase Class A ordinary shares, resulting in gross proceeds of approximately $144 million, before deducting underwriting discounts, commissions, and offering expenses.


FINANCIAL RESULTS FOR FULL YEAR 2025


Cash Position


Cash and cash equivalents were $109.4 million as of December 31, 2025, compared to $176.5 million as of December 31, 2024.


Cash Runway (Pro-Forma Post-Financing)


Based on its current operating plans, and after giving effect to the completion of the February 2026 public offering, Zura believes that its existing cash and cash equivalents are sufficient to support planned operations through at least the end of 2028.


Research and Development (R&D) Expenses


R&D expenses were $42.1 million for the year ended December 31, 2025, compared to $24.4 million for the year ended December 31, 2024. The increase was primarily driven by continued advancement of Zura’s Phase 2 tibulizumab clinical programs, including increased payments to contract research organizations and contract development and manufacturing organizations. The increase was partially offset by the reversal of a $5.0 million accrued obligation following the December 29, 2025 BAFFX17 Settlement and Release Agreement.


General and Administrative (G&A) Expenses


G&A expenses were $33.2 million for the year ended December 31, 2025, compared to $30.8 million for the year ended December 31, 2024. The increase was primarily due to higher costs to support the Company’s continued growth and advancement of its Phase 2 tibulizumab clinical programs.


Net Loss


Net loss was $68.7 million for the year ended December 31, 2025, compared to $52.4 million for the year ended December 31, 2024.


Net Loss Attributable to Class A Ordinary Shareholders


Net loss attributable to Class A ordinary shareholders was $99.4 million, or $(1.06) per basic and diluted share, compared to $45.4 million, or $(0.60) per share, for the year ended December 31, 2024.



 



ZURA BIO LIMITED








CONSOLIDATED BALANCE SHEETS








(In thousands, except share data)








 






 






 






 






 






 






 








 






 






December 31,






 






December 31,








 






 






2025






 






 






2024






 








Assets






 






 






 






 






 






 








Current assets






 






 






 






 






 






 








Cash and cash equivalents






 






$






109,407






 






 






$






176,498






 








Prepaid expenses and other current assets






 






 






2,903






 






 






 






2,246






 








Total current assets






 






 






112,310






 






 






 






178,744






 








Property and equipment, net






 






 






126






 






 






 






91






 








Other assets






 






 






1,512






 






 






 






698






 








Total assets






 






$






113,948






 






 






$






179,533






 








 






 






 






 






 






 






 








Liabilities, Redeemable Noncontrolling Interest and Shareholders’ Equity






 






 






 






 






 






 








Current liabilities






 






 






 






 






 






 








Accounts payable and accrued expenses






 






$






12,410






 






 






$






19,514






 








Total current liabilities






 






 






12,410






 






 






 






19,514






 








Total liabilities






 






 






12,410






 






 






 






19,514






 








 






 






 






 






 






 






 








 






 






 






 






 






 






 








Redeemable noncontrolling interest






 






 






—






 






 






 






11,663






 








 






 






 






 






 






 






 








Shareholders’ Equity






 






 






 






 






 






 








Class A Ordinary Shares, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 73,680,710 and 65,297,530 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively






 






 






7






 






 






 






7






 








Additional paid-in capital






 






 






326,078






 






 






 






302,705






 








Accumulated deficit






 






 






(224,547






)






 






 






(155,897






)








Total Zura Bio Limited shareholders’ equity






 






 






101,538






 






 






 






146,815






 








Noncontrolling interest






 






 






—






 






 






 






1,541






 








Total shareholders’ equity






 






 






101,538






 






 






 






148,356






 








Total liabilities, redeemable noncontrolling interest and shareholders’ equity






 






$






113,948






 






 






$






179,533






 















 







ZURA BIO LIMITED








CONSOLIDATED STATEMENTS OF OPERATIONS








(In thousands, except share and per share data)








 






 






 






 






 






 






 






 








 






 






For the Years Ended

December 31,








 






 








 






 






2025






 






 






2024






 






 








Operating expenses:






 






 






 






 






 






 






 








Research and development






 






$






42,082






 






 






$






24,401






 






 








General and administrative






 






 






33,164






 






 






 






30,788






 






 








Total operating expenses






 






 






75,246






 






 






 






55,189






 






 








Loss from operations






 






 






(75,246






)






 






 






(55,189






)






 








Other (income)/expense, net:






 






 






 






 






 






 






 








Interest income






 






 






(6,336






)






 






 






(7,998






)






 








Change in fair value of private placement warrants






 






 






—






 






 






 






5,240






 






 








Other income, net






 






 






(260






)






 






 






(28






)






 








Total other (income)/expense, net






 






 






(6,596






)






 






 






(2,786






)






 








Loss before income taxes






 






 






(68,650






)






 






 






(52,403






)






 








Income tax benefit






 






 






—






 






 






 






—






 






 








Net loss






 






 






(68,650






)






 






 






(52,403






)






 








Adjustment of redeemable noncontrolling interest






 






 






831






 






 






 






7,017






 






 








Accretion of redeemable noncontrolling interest to redemption value






 






 






4,868






 






 






 






—






 






 








Deemed dividend on extinguishment of noncontrolling interest and redeemable noncontrolling interest






 






 






(36,402






)






 






 






—






 






 








Net loss attributable to Class A Ordinary Shareholders of Zura






 






$






(99,353






)






 






$






(45,386






)






 








Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted






 






$






(1.06






)






 






$






(0.60






)






 








Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted






 






 






94,160,138






 






 






 






75,070,761






 






 







ABOUT ZURA


Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.


Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.


For more information, please visit www.zurabio.com.


FORWARD-LOOKING STATEMENTS


Any statements contained in this press release that do not describe historical facts may constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “anticipate,” “believe,” “continue,” “could,” “designed to,” “expect,” “goal,” “intend,” “may,” “outlook,” “plan,” “potential,” “should,” “will,” and similar expressions, and are based on Zura’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the development and potential therapeutic benefits of Zura’s product candidates; the timing, progress, design and results of Zura’s current and future clinical trials, including the reporting of data therefrom; the timing and potential to expand Zura’s product candidates into additional indications; the sufficiency of Zura’s cash resources and projected cash runway; and other statements that are not historical facts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such forward-looking statements. Risks and uncertainties that may cause actual results to differ materially include, but are not limited to: uncertainties inherent in the development of therapeutic product candidates, such as the risk that one or more of Zura’s current or future product candidates may not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Zura’s current or future product candidates; the risk that prior results, including signals of safety, activity or durability of effect observed in preclinical studies or earlier clinical trials, may not be replicated or may not continue in ongoing or future studies or clinical trials; the risk that modeling data indicating therapeutic potential, or clinical evidence from other drug candidates, may not be predictive of results in Zura’s current or future clinical trials; the risk that Zura’s product candidates or procedures in connection with their administration may not have the safety or efficacy profiles anticipated; risks related to the accuracy of Zura’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; uncertainties related to the timing and outcome of the regulatory approval process; unexpected litigation or other disputes; the impact of macroeconomic conditions on Zura’s business, clinical trials and financial position; and other risks and uncertainties to be described in Zura’s Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Zura as of the date hereof. Zura assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260319990599/en/
Megan K. Weinshank

Head of Corporate Affairs

ir@zurabio.com


Original: Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World CongressMarch 5, 2026 6:30 AM
Business Wire
Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece.


The poster, titled “TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis” (Abstract ID 184; Poster P.267), outlines the rationale and design of the global Phase 2 study. No clinical efficacy or safety data will be presented.


Diffuse cutaneous systemic sclerosis (“dcSSc”) is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including the lungs. Treatment options remain limited, highlighting the need for therapeutic approaches that address multiple drivers of disease biology.


TibuSURE is the first clinical trial designed to evaluate the dual inhibition of interleukin-17A (“IL-17A”) and B-cell activating factor (“BAFF”) in dcSSc. Tibulizumab is an investigational bispecific antibody engineered to simultaneously neutralize IL-17A and BAFF, two cytokines implicated in inflammation, autoimmunity and fibrotic progression in SSc. By targeting complementary immune pathways, tibulizumab represents a differentiated investigational strategy intended to modulate both inflammatory and fibrotic disease processes.


The ongoing global Phase 2 study is expected to enroll approximately 80 adults who will be randomized 1:1 to receive tibulizumab or placebo every four weeks for 24 weeks, followed by a 28-week open-label extension. The primary endpoint is change from baseline in modified Rodnan Skin Score at Week 24. Topline results are currently anticipated in the first half of 2027.


Poster Presentation Details



Poster Number: P.267



Presenting Author: Christopher Denton, M.D., Ph.D., FRCP, Professor of Experimental Rheumatology at University College London



Session Times (Local Athens Time, EET / UTC+2):


Friday, March 6, 2026: 13:20–14:25



Saturday, March 7, 2026: 12:35–13:50






ABOUT TIBULIZUMAB (ZB-106)


Tibulizumab is an investigational, humanized, tetravalent dual-antagonist antibody engineered by fusing Taltz® (ixekizumab) and tabalumab to bind to and neutralize both IL-17A and BAFF. It is currently being evaluated in two Phase 2 clinical studies in adults with hidradenitis suppurativa and systemic sclerosis. Prior to in-licensing by Zura, Phase 1/1b studies were conducted in patients with Sjögren’s syndrome and rheumatoid arthritis.


Tibulizumab is an investigational compound and has not been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority.


ABOUT ZURA


Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.


Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.


For more information, please visit www.zurabio.com.


FORWARD-LOOKING STATEMENTS


Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe,” “designed to,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on Zura’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of Zura’s product candidates; the timing of enrollment, initiation, progress, and results of Zura’s current and future clinical trials, including TibuSURE, including reporting of data therefrom; and Zura’s plans to present the design of its Phase 2 TibuSURE clinical trial at the Systemic Sclerosis World Congress. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Zura’s current or future product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Zura’s current or future product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Zura’s current or future product candidates; the risk that modeling data indicating therapeutic potential, or clinical evidence from other drug candidates, will not be replicated in ongoing or future studies or clinical trials involving Zura’s current or future product candidates; the risk that Zura’s current or future product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that Zura anticipates; risks regarding the accuracy of Zura’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts of macroeconomic conditions on Zura’s business, clinical trials and financial position; and other risks and uncertainties that are described in Zura’s Annual Report on Form 10-K for the year ended December 31, 2024, as supplemented by its Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025 and September 30, 2025, and other filings with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Zura as of the date hereof, and Zura assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260305051263/en/
Megan K. Weinshank

Head of Corporate Affairs

ir@zurabio.com


Original: Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

Zura Bio to Participate in Upcoming Investor ConferencesMarch 2, 2026 6:30 AM
Business Wire
Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conferences:


Leerink Global Healthcare Conference



Location: Miami, FL



Fireside chat: Tuesday, March 10, 2026, at 2:20 p.m. ET



Investor meetings: Management will meet with investors



Jefferies Biotech on the Beach Summit



Location: Miami, FL



Date: Wednesday, March 11, 2026



Investor meetings: Management will meet with investors



A live webcast of the Leerink Global Healthcare Conference fireside chat will be available in the Investors section of the Company’s website under News & Events. A replay will be accessible for at least 30 days following the event.


ABOUT ZURA


Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. The Company’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.


Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.


For more information, please visit www.zurabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260302608307/en/
Megan K. Weinshank

Head of Corporate Affairs

ir@zurabio.com


Original: Zura Bio to Participate in Upcoming Investor Conferences

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesFebruary 27, 2026 6:30 AM
Business Wire
Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre-funded warrants on February 26, 2026.


The offering consisted of 21,200,000 Class A ordinary shares priced at $6.25 per share, along with pre-funded warrants for 1,800,000 Class A ordinary shares priced at $6.249 per warrant, which included 3,000,000 additional Class A ordinary shares sold upon exercise in full by the underwriters of their option to purchase additional shares of stock in the offering. All shares and pre-funded warrants were sold by Zura.


Gross proceeds from the offering were approximately $144 million, before deducting underwriting discounts and commissions and other offering expenses payable by Zura.


Leerink Partners, Piper Sandler and Cantor acted as joint bookrunning managers for the offering. Wedbush PacGrow acted as lead manager.


The Class A ordinary shares and pre-funded warrants were offered by Zura pursuant to a shelf registration statement on Form S-3, as amended (Registration No. 333-281905), that was filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective on September 17, 2024. The offering was made by means of a prospectus supplement and accompanying prospectus filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained by visiting the SEC’s website at www.sec.gov.


ABOUT ZURA


Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.


Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260227534816/en/
Megan K. Weinshank

Head of Corporate Affairs

ir@zurabio.com


Original: Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 25, 2026 6:30 AM
Business Wire
Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 18,200,000 Class A ordinary shares at a price to the public of $6.25 per share and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase 1,800,000 Class A ordinary shares at a price to the public of $6.249 per pre-funded warrant, which equals the public offering price per Class A ordinary share, less the $0.001 exercise price of each pre-funded warrant. In addition, Zura has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 Class A ordinary shares at the public offering price, less underwriting discounts and commissions. All of the Class A ordinary shares and pre-funded warrants are to be sold by Zura.


The gross proceeds to Zura from the offering are expected to be $125 million, before deducting underwriting discounts and commissions and other offering expenses payable by Zura. The offering is expected to close on February 26, 2026, subject to the satisfaction of customary closing conditions.


Leerink Partners, Piper Sandler and Cantor are acting as joint bookrunning managers for the proposed offering. Wedbush PacGrow is acting as lead manager for the proposed offering.


The Class A ordinary shares and pre-funded warrants are being offered by Zura pursuant to a shelf registration statement on Form S-3, as amended (Registration No. 333-281905) that was originally filed with the Securities and Exchange Commission (the “SEC”) on September 3, 2024 and subsequently declared effective by the SEC on September 17, 2024. The offering is being made only by means of a prospectus supplement and accompanying prospectus that will form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or via email at syndicate@leerink.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or via email at prospectus@psc.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, via e-mail at prospectus@cantor.com.


This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


ABOUT ZURA


Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. The Company’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.


Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.


FORWARD-LOOKING STATEMENTS


Any statements contained in this press release that do not describe historical facts may constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe,” “designed to,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on Zura’s current beliefs and expectations. These forward-looking statements include statements regarding the expected gross proceeds from the offering and the closing date of the offering. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties related to market conditions, the satisfaction of customary closing conditions related to the public offering, and such other risks and uncertainties that are described in Zura’s Annual Report on Form 10-K for the year ended December 31, 2024, as supplemented by its Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025 and September 30, 2025, and other filings with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Zura as of the date of this release, and Zura assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260225821534/en/
Megan K. Weinshank

Head of Corporate Affairs

ir@zurabio.com


Original: Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of DirectorsFebruary 23, 2026 6:30 AM
Business Wire
Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date.


“Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a global scale,” said Amit Munshi, Chairman of the Board. “As we advance our Phase 2 programs and evaluate new growth opportunities, their experience will be instrumental. Their decision to join the Board reflects their conviction in our strategy and pipeline.”


“Neil has been a valued member of our Board since the Company’s formative stages,” added Mr. Munshi. “Following his decision to accept a full-time role that limits his ability to continue serving on the Board, we want to express our sincere appreciation for his significant contributions to Zura. Neil has been a critical participant on our R&D Committee, and his insight and dedication have helped shape the Company. We are grateful for his service and wish him continued success in his future endeavors.”


Mark Eisner, M.D., M.P.H.


Dr. Mark Eisner, M.D., M.P.H., is a biotechnology executive with more than 25 years of leadership in clinical development and immunology. He currently serves as Executive Vice President and Chief Medical Officer of Vir Biotechnology, where he oversees clinical development, regulatory sciences, and medical affairs. Previously, he served as Chief Medical Officer at Sonoma Biotherapeutics and FibroGen, and spent nearly 11 years at Genentech/Roche, including as Senior Vice President and Global Head of Product Development for Immunology, Infectious Disease, and Ophthalmology. In that role, he led multinational development programs and global regulatory submissions across major therapeutic areas. Prior to entering industry, Dr. Eisner was Professor of Medicine and Anesthesia at the University of California, San Francisco.


“Successfully advancing innovative biologics requires rigorous clinical strategy and disciplined execution,” said Dr. Eisner. “Zura has taken a data-driven and scientifically grounded approach to development, and I look forward to contributing my experience in guiding programs through critical clinical and regulatory milestones.”


Ajay Nirula, M.D., Ph.D.


Dr. Ajay Nirula, M.D., Ph.D., is a physician-scientist and biotechnology executive with more than two decades of leadership in immunology research and clinical development. He currently serves as Executive Vice President and Head of Research and Development at Recludix Pharma. Previously, Dr. Nirula served as Senior Vice President and Immunology Therapeutic Area Head at Eli Lilly and Company, where he led discovery research and early- and mid-phase clinical development in immunology. During his tenure, he helped establish immunology as a core therapeutic area at Lilly, contributing to four globally approved medicines and advancing more than ten product candidates into clinical development. While at Lilly, he oversaw the development of tibulizumab prior to its licensing to Zura and has subsequently served on Zura’s Scientific Advisory Board, continuing his engagement with the program. Prior to Lilly, Dr. Nirula held leadership roles at Amgen, Biogen Idec, and Merck & Co., advancing programs across multiple immune-mediated diseases.


“Having overseen tibulizumab’s development while at Lilly, I have long believed in the strength of its dual-pathway design,” said Dr. Nirula. “By simultaneously targeting IL-17 and BAFF, Zura’s strategy is designed to address complementary drivers of autoimmune disease, and I’m excited to support the advancement of this dual-pathway bispecific program.”


ABOUT ZURA


Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. The Company’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.


Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.


For more information, please visit www.zurabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223718399/en/
Megan K. Weinshank

Head of Corporate Affairs

ir@zurabio.com


Original: Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech SummitFebruary 4, 2026 6:30 AM
Business Wire
Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that its senior leadership team will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 11:00 AM ET in New York, NY. The Company will also conduct one-on-one investor meetings on the same day.


A live webcast of the presentation will be available in the Investors section of the Company’s website under News & Events. A replay will remain archived for at least 30 days.


ABOUT ZURA


Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. The Company’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.


Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.


For more information, please visit www.zurabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260204391348/en/
Megan K. Weinshank

Head of Corporate Affairs

ir@zurabio.com


Original: Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

ZURA MONSTER

ZURA BIO BEAST BEATING THE MARKET TODAY

ZURA dip buy

Ownership Summary
Institutional Ownership 69.92%
Total Shares Outstanding (millions) 62
Total Value of Holdings (millions) $56

Active Positions | Holders | Shares
Increased Positions | 33 | 5,597,300
Decreased Positions | 41 | 2,495,259
Held Positions | 23 | 35,169,219
Total Institutional Shares | 97 | 43,261,778

https://www.nasdaq.com/market-activity/stocks/zura/institutional-holdings

$ZURA

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2025

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported that on July 15, 2025, the Company granted inducement awards consisting of options to purchase up to 890,950 Class A Ordinary Shares (the “Options”) to seven newly hired employees, which includes an award of 672,000 Options granted to Eric Hyllengren, the newly appointed Chief Financial Officer. These awards were approved by the Compensation Committee and the Board and granted outside the Company’s 2023 Equity Incentive Plan (the “Plan”), with a grant date of July 15, 2025, as inducements material to the new employees’ employments, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and conditions and other provisions set forth in the Company’s Plan and the award agreements thereunder.

One fourth (1/4th) of the shares subject to each Option shall vest on the applicable vesting commencement date, and one twelfth (1/12th) of the remaining shares subject to each Option shall vest in equal quarterly installments thereafter, subject to the employee’s continuous service through such vesting date.

ABOUT ZURA BIO
Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases. The Company’s pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.

Zura Bio’s lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. Additional product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.

For more information, please visit www.zurabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250717937915/en/

Megan K. Weinshank
Head of Corporate Affairs
ir@zurabio.com

https://ih.advfn.com/stock-market/NASDAQ/zura-bio-ZURA/stock-news/96452384/zura-bio-reports-inducement-grants-under-nasdaq-li

$ZURA

zura..........................................................................A/H

Price Target
Based on short-term price targets offered by six analysts, the average price target for Zura Bio Limited comes to $13.67. The forecasts range from a low of $3.00 to a high of $26.00. The average price target represents an increase of 959.69% from the last closing price of $1.29.

Zura Bio Limited currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations.

Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations.

https://www.zacks.com/stock/research/ZURA/price-target-stock-forecast

(Price targets are not always met. But a nice increase is certainly possible here)

=====================

As at March 2025, Zura Bio had cash of US$171m and no debt.

https://finance.yahoo.com/news/were-not-very-worried-zura-111812043.html?guccounter=1&guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=AQAAAERoScfRjD0xoJh719k-1jchUgKL6s-wQcZk__Il0wtfgTMQ-rDadWD5deDcS5N2k-HlT_KLwa24DTMMwzxrdeuaZc9DzwSy__95rhgQwNU_bxLneIsr80_WEyb0kIZalNQYguKqwyIIGbg62ppvCXDcqArr8kVmtD9GscXb4u-_

$ZURA 💹

ZURA, recent 52 week low

ZURA under $3

ZURA under $5

ZURA under $5

ZURA under $4

ZURA under $5

ZURA under $10

ZURA under $5

Volume

Just sell and move on
Life is too short

So true but it would be nice to let investors know if there is a problem.

Well, the best I can say is not all biotech start ups are destined to be to be the next Vertex

Question is, what is wrong with this company?

ZURA new 52 week low

ZURA new 52 week low

What is wrong with this dog!?

Oppenheimer has initiated coverage of ZURA with a price target of 17.

Seems like classic pump and dump action on this one.

7,82

zura HITS 8.80 ON 7AM SESSION THEN DROPS -$1

ON WATCH, TRYING TO FIGURE OUT HOW BIG OR NOT THE NEWS IS

Added 8.49

Looking real good

ZURA Looking Good

Warrants sellers at these levels are brainless fools, hands down.

Movement

Wild

END GOAL SHOULD BE HUUUUUUUUUUUUGE! WE SHALL SEE

ROOT-CAUSE ANALYSIS******
https://finance.yahoo.com/quote/ZURA/holders?p=ZURA

ZURA: YEP!! Yet a very unusual play here, in that NO precipitous CRASHING today. (ODD stuff!)

ZURA (& ZURAW): YEP!! But surprisingly, BOTH holding GREEN today --- despite yesterday's huge run-up. And curiously, its WARRANTS are consistently holding nearly 3-times-more GREEN all day today, compared to the Parent firm.


I'm relaxing in my HOT (Blonde Chicks) TUB right now --- see me, above, LIVE --- over here in (balmy) San Diego, CA!!

STABILIZING! LOOKS LIKE, NOT BAD AT ALL FOR THIS PARTICULAR POINT IN TIME. LOOKING FORWARD FOR BETTER DAYS. VERY SOLID CONSOLIDATION!
THE EXPLOSION TO $37 WAS QUITE SPORADIC, MOVE WITH CAUTION